Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-02
2007-01-02
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S183000, C514S228500, C514S233200, C514S252160, C514S259300, C540S481000, C540S600000, C544S061000, C544S117000, C544S281000
Reexamination Certificate
active
10660878
ABSTRACT:
Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 4298734 (1981-11-01), Temple, Jr.
patent: 4472398 (1984-09-01), Meszaros et al.
patent: 4918074 (1990-04-01), Tsuda et al.
patent: 6150356 (2000-11-01), Lloyd et al.
patent: 6660742 (2003-12-01), Lee
patent: 3309432 (1983-09-01), None
patent: 0 163 240 (1985-12-01), None
patent: 0 183 848 (1986-06-01), None
patent: 0 217 142 (1987-04-01), None
patent: 0 254 119 (1988-01-01), None
patent: 0 304 001 (1989-02-01), None
patent: 0 565 096 (1993-10-01), None
patent: 1596320 (1981-08-01), None
patent: 61-227584 (1986-10-01), None
patent: 63-60985 (1988-03-01), None
patent: 63-107983 (1988-05-01), None
patent: 1-271751 (1989-10-01), None
patent: 8-301871 (1996-11-01), None
patent: WO 85/04172 (1985-09-01), None
patent: WO 90/10632 (1990-09-01), None
patent: WO 93/14083 (1993-07-01), None
patent: WO 97/35550 (1997-10-01), None
patent: WO 98/18475 (1998-05-01), None
patent: WO 98/18476 (1998-05-01), None
Yi et al., Controlling Potassium Channel activities, PNAS, vol. 98, No. 20, pp. 11016-23, Sep. 2001.
Bremner et al., Therapy of Crohn's Disease in childhood, Expert Opin. Pharmacother. 3(7), pp. 809-825, 2002.
Singh et al., Immune therapy in inflammatory bowel disease and models of colitis, British Journal of Surgery, 88, 1558-1569, 2001.
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21stCentury, Eur. J. Surg. Suppl 582, pp. 90-98, 1998.
Li G-R, Feng J, Yue L, Carrier M, Nattel S.Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 1996; 78:689-696.
Feng J, Wible B, Li GR, Wang Z, Nattel S.Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ Current in cultured adult human atrial myocytes. Circ. Res. 1997 Apr.: 80(4):572-579.
Amos GJ, Wettwer E. Metzger F, LiQ, Himmel HM, Ravens U.Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol (Lond). 1996; 4911:31-50.
Cochran et al., “Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K+-channels,” Eur J Neurosci: Nov. 2001:14(9):1455-63.
Coleman et al., “Subunit composition of Kv1 channels in human CNAS,” J Neurochem. Aug. 1999;73(2):849-58.
Davies et al., “Kv channel subunit expression in rat pulmonary arteries,” Lung. 2001;179(3):147-61. Epub Feb. 4, 2002.
Frey et al., “Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine,” Neurogastroenterol Motif. Dec. 2000;12(6):509-16.
Hanson et al., “UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation,” British Journal of Pharmacology (1999), 128, 1707-1716.
Hatton et al., “Functional and molecular expression of a voltage-dependent K(+) channel (Kv1.1) in interstitial cells of Cajal,” J Physiol. Jun. 1, 2001;533 (Pt 2):215-27.
Koh et al., “Contribution of delayed rectifier potassium currents to the electrical activity of murine colonic smooth muscle,” J Physiol. Mar. 1, 1999; 515 (Pt 2):475-87.
Kourrich et al., “Kallotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats,” Behav Brain Res. Apr. 8, 2001;120(1):35-46.
Lopantsev et al., “Hyperexcitability of CA3 pyramidal cells in mice lacking the potassium channel subunit Kv1.1.” Epilepsia. Dec. 2003;44(12):1506-12.
MacDonald et al., “Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion,” Mol Endocrinol. Aug. 2001;15(8):1423-35.
MacDonald et al., “Voltage-dependent K(+( channels in pancreatic beta cells; role, regulation and potential as therapeutic targets,” Diabetologia. Aug. 2003;46(8):1048-62. Epub Jun. 27, 2003.
Pozeg et al., “In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats,” Circulation. Apr. 22, 2003;107(15):2037-44, Epub Apr. 14, 2003.
Rho et al., “Developmental seizure susceptibility of kv1.1 potassium channel knockout mice,” Dev Neurosci. Nov. 1999;21 (3-5):320-7.
Shah et al., “Immunosuppressiv effects of a Kv1.3 ubgubutirm” Cellular Immunology 221, (2003), 100-106.
Vianna-Jorge et al., “Shaker-type Kv1 channel blockers increase the peristatic activity of guinea-pig ileum by stimulating acetylcholine and tachykinins release by the enterio nervous system,” Br J Pharmacol. Jan. 2003; 138(1):57-62.
Wickenden, “Potassium channels as anti-epileptic drug targets,” Neuropharmacology. Deb. 2002;43(7):1055-60.
Wulff et al., “Potassium channels as therapeutic targets for autoimmune disorders,” Current Opinion in Drug Discovery & Develpment 2003 6(5):640-647.
Xu et al., “The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity,” Proc natl Acad Sci U S A. mar. 2, 2004;101(9):3112-7. Epub Feb. 23, 2004 (epublished Feb. 23, 2004).
Atwal Karnail S.
Bhandaru Rao S.
Finlay Heather
Lloyd John
Vaccaro Wayne
Bogie Terence J.
Bristol--Myers Squibb Company
O'Brien Maureen P.
Rao Deepak
LandOfFree
Heterocyclic dihydropyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic dihydropyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic dihydropyrimidine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724565